Leo Lee | CEO
Leo has served on the Board since December 2017 and was appointed CEO on 23 January 2019. Leo is a Senior executive with over 20 years of experience in Pharmaceutical innovation, commercialisation, regulatory and policy. He has worked in North America, Asia and has lived and worked in Japan the last 12 years. Leo was previously President of Allergan, Japan and former President of Merck Japan.
Professor Graham Vesey | Chief Scientific Officer
Graham is a co-founder and founding CEO of Regeneus and has served on the Board since incorporation. Graham was appointed Chief Scientific Officer in November 2014. Graham is a successful biotechnology entrepreneur, technology innovator and inventor and a highly regarded scientist. Graham was a co-founder and Executive Director of BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.
John Bird | Chief Financial Officer
John is the Chief Financial and Operations Officer. John joined Regeneus in 2014. He is an experienced CFO with over 25 years in senior finance and operations roles in technology, service and manufacturing organisations. John undertook his undergraduate studies while working as an auditor for KPMG and has subsequently gained a wealth of financial and operational experience in Australian and US private and listed companies including GE, AWA Ltd, TAB Ltd, Shufflemaster. John is a CPA with a Bachelor of Economics from Macquarie University and is a member of the Australian Institute of Company Directors.
Dr Charlotte Morgan | Head of R&D
Charlotte is Head of Research and Development and Production. Charlotte joined Regeneus in 2012. She started her career in the UK as a research scientist in the water and microbiology industries. After a move to Australia, she completed a PhD in precise microbiological reference materials, and gained a position as R&D manager at BTF. Since joining Regeneus, the emphasis has been on animal and human cell therapy product development. Our research and development team are responsible for investigational product manufacture for all of our cell therapy product clinical trials and for our human cancer vaccine. They have manufactured investigational products for both animal and human trials.
Sandra McIntosh | Company Secretary, Head of Corporate Affairs
Sandra is the Company Secretary and is responsible for investor relations. Sandra joined the company in 2009. She brings more than 20 years management experience in HR, customer service and finance. Sandra previously worked at BTF where she was the Global Customer Service Manager. Sandra has successfully completed certificates of Applied Corporate Governance through Governance Institute of Australia and has an AIRA Diploma in Investor Relations.